Related Experiment Video
Updated: Jun 19, 2026
09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
New oral drugs for multiple sclerosis
Claudio Gasperini1, S Ruggieri
1Centro Sclerosi Multipla, Azienda Ospedaliera S. Camillo-Forlanini, Rome, Italy. c.gasperini@libero.it
Summary
New oral therapies offer improved options for multiple sclerosis (MS) management. This review highlights advances in oral treatments, addressing limitations of current disease-modifying therapies for relapsing-remitting and secondary progressive MS.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Disease-modifying treatments for multiple sclerosis (MS) are available but have limitations.
- Current therapies are only partially effective and can cause side effects, impacting patient adherence.
- There is a need for novel, well-tolerated oral therapeutic approaches for MS.
Purpose of the Study:
- To review current and novel oral treatment approaches for multiple sclerosis (MS).
- To discuss advances in oral therapies for managing MS disease progression.
- To evaluate the safety and efficacy of emerging oral agents.
Main Methods:
- Literature review of pivotal clinical studies and reports.
- Focus on oral therapeutic agents for multiple sclerosis.
- Analysis of safety and efficacy data for new oral therapies.
Main Results:
- Several oral agents, including fingolimod, fumaric acid, cladribine, teriflunomide, and laquinimod, show promising results.
- These new therapies aim to improve efficacy in halting MS disease progression.
- Evaluation of safety profiles and patient adherence associated with oral MS treatments.
Conclusions:
- Oral therapies represent a significant advancement in multiple sclerosis treatment.
- Novel oral agents offer potential for improved disease modification and patient outcomes.
- Continued research into oral therapeutic approaches is crucial for effective MS management.
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...